Zenlabs Ethica Ltd
₹ 37.0
0.76%
05 Jun
- close price
About
Incorporated in 1993, Zenlabs Ethica Ltd deals in marketing and distribution of pharmaceutical products.[1]
Key Points
- Market Cap ₹ 24.1 Cr.
- Current Price ₹ 37.0
- High / Low ₹ 40.0 / 16.5
- Stock P/E 1,204
- Book Value ₹ 13.1
- Dividend Yield 0.00 %
- ROCE 5.07 %
- ROE 0.21 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.83 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -3.70% over past five years.
- Company has a low return on equity of 2.39% over last 3 years.
- Company might be capitalizing the interest cost
- Promoter holding has decreased over last 3 years: -6.16%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 15.09 | 78.73 | 69.85 | 65.37 | 58.50 | 56.64 | 69.09 | 66.89 | 58.56 | 51.42 | 46.92 | |
| 0.05 | 14.89 | 77.28 | 68.00 | 63.28 | 59.20 | 54.89 | 66.70 | 63.98 | 56.15 | 48.84 | 45.13 | |
| Operating Profit | -0.05 | 0.20 | 1.45 | 1.85 | 2.09 | -0.70 | 1.75 | 2.39 | 2.91 | 2.41 | 2.58 | 1.79 |
| OPM % | 1.33% | 1.84% | 2.65% | 3.20% | -1.20% | 3.09% | 3.46% | 4.35% | 4.12% | 5.02% | 3.82% | |
| 0.00 | -0.03 | 0.08 | 0.10 | 0.10 | 0.05 | 0.11 | 0.09 | -0.45 | 0.30 | 0.04 | -1.90 | |
| Interest | 0.00 | 0.02 | 0.10 | 0.09 | 0.07 | 0.23 | 0.29 | 0.37 | 0.53 | 0.83 | 0.93 | 0.81 |
| Depreciation | 0.01 | 0.06 | 0.20 | 0.20 | 0.23 | 0.29 | 0.71 | 0.89 | 1.25 | 1.29 | 1.26 | 0.89 |
| Profit before tax | -0.06 | 0.09 | 1.23 | 1.66 | 1.89 | -1.17 | 0.86 | 1.22 | 0.68 | 0.59 | 0.43 | -1.81 |
| Tax % | 16.67% | -88.89% | 21.95% | 29.52% | 32.80% | -36.75% | 10.47% | 36.07% | 26.47% | 27.12% | 37.21% | 6.63% |
| -0.07 | 0.17 | 0.95 | 1.16 | 1.26 | -0.73 | 0.77 | 0.78 | 0.49 | 0.42 | 0.27 | -1.94 | |
| EPS in Rs | -0.18 | 0.26 | 1.46 | 1.78 | 1.94 | -1.12 | 1.18 | 1.20 | 0.75 | 0.65 | 0.41 | -2.98 |
| Dividend Payout % | 0.00% | 0.00% | 16.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 33.21% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -4% |
| 3 Years: | -11% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -23% |
| 5 Years: | -52% |
| 3 Years: | -72% |
| TTM: | -93% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 3% |
| 3 Years: | -7% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 5% |
| 3 Years: | 2% |
| Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.62 | 6.20 | 6.20 | 6.20 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 |
| Reserves | -1.65 | -1.41 | -0.41 | 0.81 | 1.77 | 0.90 | 2.05 | 2.82 | 3.19 | 3.61 | 3.92 | 2.00 |
| 0.00 | 1.09 | 0.96 | 0.85 | 0.60 | 0.73 | 2.60 | 3.90 | 5.85 | 14.86 | 12.71 | 10.98 | |
| 1.77 | 24.49 | 26.62 | 21.96 | 26.01 | 25.85 | 21.04 | 24.66 | 27.95 | 15.28 | 17.48 | 17.72 | |
| Total Liabilities | 3.74 | 30.37 | 33.37 | 29.82 | 34.89 | 33.99 | 32.20 | 37.89 | 43.50 | 40.26 | 40.62 | 37.21 |
| 0.06 | 1.68 | 1.50 | 1.33 | 1.36 | 1.12 | 3.51 | 3.53 | 5.03 | 3.70 | 2.29 | 1.87 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 1.25 | 0.95 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.00 |
| 3.68 | 27.44 | 30.92 | 27.79 | 32.83 | 32.17 | 27.99 | 33.66 | 37.77 | 35.86 | 37.63 | 35.34 | |
| Total Assets | 3.74 | 30.37 | 33.37 | 29.82 | 34.89 | 33.99 | 32.20 | 37.89 | 43.50 | 40.26 | 40.62 | 37.21 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 0.92 | -1.06 | 0.36 | 0.80 | 0.45 | -8.41 | -0.38 | 1.52 | -9.06 | 3.83 | 4.06 | |
| 0.00 | -1.69 | -0.02 | -0.03 | -0.22 | 0.01 | 0.15 | 0.00 | -1.47 | 0.11 | 0.14 | 0.00 | |
| 0.00 | 3.23 | -0.27 | -0.23 | -0.14 | -0.03 | -0.52 | 0.31 | 0.06 | 8.24 | -3.08 | -2.95 | |
| Net Cash Flow | 0.02 | 2.47 | -1.35 | 0.09 | 0.44 | 0.43 | -8.78 | -0.07 | 0.11 | -0.71 | 0.88 | 1.11 |
| Free Cash Flow | 0.02 | -0.77 | -1.08 | 0.33 | 0.49 | 0.40 | -8.35 | -0.41 | -0.03 | -9.08 | 3.96 | 4.06 |
| CFO/OP | -40% | 460% | -73% | 19% | 38% | -64% | -475% | -11% | 62% | -371% | 157% | 234% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 398.14 | 107.65 | 126.40 | 139.37 | 138.76 | 121.67 | 109.57 | 118.41 | 129.21 | 138.70 | 122.13 | |
| Inventory Days | 249.62 | 34.42 | 11.12 | 31.23 | 33.95 | 40.46 | 56.05 | 77.85 | 100.05 | 128.43 | 161.14 | |
| Days Payable | 665.46 | 136.41 | 125.88 | 161.27 | 165.31 | 150.28 | 141.30 | 174.04 | 101.21 | 140.00 | 165.22 | |
| Cash Conversion Cycle | -17.70 | 5.66 | 11.64 | 9.33 | 7.40 | 11.85 | 24.32 | 22.21 | 128.04 | 127.13 | 118.05 | |
| Working Capital Days | 4.84 | 13.40 | 21.95 | 28.42 | 24.02 | 27.97 | 35.34 | 34.98 | 47.31 | 52.74 | 39.44 | |
| ROCE % | -2.99% | 9.94% | 21.06% | 23.96% | 24.13% | -11.05% | 12.02% | 13.04% | 12.44% | 7.01% | 5.69% | 5.07% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Capital Turnover Ratio times |
|
||||||||||
| Number of Permanent Employees number |
|||||||||||
| Trade Receivables Turnover Ratio times |
|||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Jun - Submission of Newspaper Advertisement for publication of extract of audited financial results of quarter and year ended 31st March 2026
-
Announcement under Regulation 30 (LODR)-Change in Management
29 May - Board approved FY2026 audited results, unmodified audit report, and appointed Nikunj Goel as Company Secretary.
-
Non-Applicability Of Regulation 23(9) Of SEBI (LODR), 2015
29 May - Company says RPT disclosure for half year ended 31 March 2026 is not applicable under Regulation 23(9).
-
Appointment of Company Secretary and Compliance Officer
29 May - Nikunj Goel appointed Company Secretary and Compliance Officer effective 29 May 2026.
-
APPROVAL OF AUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2026
29 May - Zenlabs Ethica approved FY26 audited results, unmodified audit opinion, and appointed a new company secretary.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
a) ZEL is a part of the Preet Remedies Group. It is a WHO–GMP certified contract manufacturing pharmaceutical firm which operates across manufacturing and distributing diversified pharmaceutical formulations under multiple divisions (Zenlabs, Coles Pharma, Mega Star), servicing both domestic and international markets including Southeast Asia.
b) The company does third party manufacturing for Preet Remedies Group which has 5 production units namely Preet Remedies Pvt. Ltd., Oasis Pharma & Phytomolecules Pvt. Ltd., Quixotic Healthcare Unit I & II, and Alpha Products. At any of these facilities, the minimum
order quantity offered is 2000 boxes
of drugs.
c) The company is also into private label manufacturing of different pharmaceutical products.